Antibodies have been used for more than 100 years in the therapy of infectious diseases,
but a new generation of highly potent and/or broadly cross-reactive human monoclonal …

Recent Ebola virus disease epidemics have highlighted the need for effective vaccines and
therapeutics to prevent future outbreaks. Antibodies are clearly critical for control of this …

Zika virus (ZIKV), a mosquito-borne flavivirus, is a current global public health concern. The
flavivirus envelope (E) glycoprotein is responsible for virus entry and represents a major …

Without an approved vaccine or treatments, Ebola outbreak management has been limited
to palliative care and barrier methods to prevent transmission. These approaches, however …

The recent Ebola virus (EBOV) epidemic highlighted the need for effective vaccines and
therapeutics to limit and prevent outbreaks. Host antibodies against EBOV are critical for …

Antibodies are promising post-exposure therapies against emerging viruses, but which
antibody features and in vitro assays best forecast protection are unclear. Our international …

Antibodies targeting the Ebola virus surface glycoprotein (EBOV GP) are implicated in
protection against lethal disease, but the characteristics of the human antibody response to …

Ebola virus (EBOV) is considered one of the most aggressive infectious agents and is
capable of causing death in humans and nonhuman primates (NHPs) within days of …

Ebola viruses cause hemorrhagic disease in humans and nonhuman primates with high
fatality rates. These viruses pose a significant health concern worldwide due to the lack of …

Background For most classes of drugs, rapid development of therapeutics to treat emerging
infections is challenged by the timelines needed to identify compounds with the desired …